Fig. 3.

IFNα activates PBMCs and stimulates nonT PBMCs (monocytes) to express CXCL10. A qPCR was used to detect the activation marker IFNγ and IL-2 and chemokine CXCL10 in healthy PBMCs treated with 20 ng/mL of IFNα and IFNγ. B Immune activation marker IFNγ and M1 and M2 markers in nonT PBMCs (T lymphocytes were excluded) were investigated using qPCR after IFNα treatment for 2 h and 24 h. C The activation marker IFNγ, IL-2 and cytotoxic marker GZMB, PRF1, and anti-apoptosis marker BCL-2 were detected by qPCR in 20 ng/mL of IFNα-treated CD4⁺ T cells and D CD8⁺ T cells. E The healthy PBMCs were treated with 20 ng/mL of IFNα and analyzed by flow cytometry to F detect the IFNγ protein levels in nonT PBMCs, CD4⁺ T, and CD8⁺ T cells. CD4⁺ T and CD8⁺ T were gated by staining anti-CD45-Pacific blue, anti-CD3-APC/Cy7, anti-CD8-Alexa488, anti-CD4-PE/Cy7, and anti-IFNγ-PE.*p < 0.05